ImmuPharma plc (LON:IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, has said that it has entered into agreements with two specialist US healthcare investors for a..
ImmuPharma plc (LON:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announced today that the Company’s Annual General Meeting confirmed for Thursday, 18 June 2020 @ 10.30am,..
ImmuPharma plc (LON:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company provided today a progress update on activities around Covid-19. On the 30th March 2020, ImmuPharma announced..
ImmuPharma plc (LON:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, has today announced its final results for the twelve months ended 31 December 2019. Key Highlights..
ImmuPharma PLC (LON:IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, has today announced subscriptions to raise £1.5 million through the issue of 15,000,000 new ordinary share..
ImmuPharma PLC (LON:IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, noted today that further to its announcement on 17 February 2020, Incanthera plc, a specialist oncology..
ImmuPharma PLC (LON: IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, announced today an update on activities with Avion Pharmaceuticals LLC following the successful licence and..
ImmuPharma plc (LON: IMM | Euronext Growth: ALIMM), a specialist drug discovery and development company, has today announced that, this morning at approximately 09.00am (GMT), ImmuPharma will commence trading on..
ImmuPharma PLC (LON: IMM), a specialist drug discovery and development company, has announced that, further to the announcement of 13th December 2019, that its shares will be admitted to trading..
ImmuPharma (LON:IMM) is the topic of conversation when The Life Sciences Division’s Executive Director and Head of Research Navid Malik caught up with DirectorsTalk for an exclusive interview. Q1: Firstly,..
ImmuPharma PLC (LON: IMM), a specialist drug discovery and development company has announced that its shares will be admitted to trading on Euronext Growth Brussels under ticker ‘ALIMM’ following the..
Life Science Division Executive Director and Head of Research Dr Navid Malik joins DirectorsTalk to discuss ImmuPharma plc (LON: IMM). Navid provides an overview of the Life Science Division and..
ImmuPharma (LON:IMM) announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals, a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women..
ImmuPharma plc (LON: IMM) Non-Executive Chairman Tim McCarthy joins DirectorsTalk to discuss a licencing and development agreement with US speciality pharmaceutical company Avion. Tim talks us through the key highlights..
ImmuPharma PLC (LON:IMM), a specialist drug discovery and development company, have announced a licence and development agreement with Avion Pharmaceuticals LLC, for the exclusive rights to Lupuzor™ in North America..
ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company, has today announced its interim results for the six months ended 30th June 2019. Key Highlights (including post Period..
ImmuPharma plc (LON:IMM) is the topic of conversation when The Life Sciences Division’s Executive Director Navid Malik caught up with DirectorsTalk for an exclusive interview. Q1: Navid, firstly can you..
ImmuPharma plc (LON: IMM) is the topic of conversation when Navid Malik Executive Director at The Life Sciences Division joins DirectorsTalk. Navid provides some background to TLSD and it’s interest..
The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announced an update report on ImmuPharma plc, a pharmaceutical development company listed on AIM of..
